Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2023-10-11 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The document is an announcement detailing the top-line results of a Phase 3 clinical trial for a pharmaceutical product (ALK's tree tablet). It discusses efficacy endpoints, safety profiles, and future regulatory dialogue. This content is characteristic of a press release or an announcement regarding research and development progress, which often precedes a formal financial filing or is released independently to inform investors and the market about significant operational milestones. Since it is a detailed announcement of clinical trial success and future plans, it is not a standard regulatory report (like 10-K or IR), nor is it a transcript (CT) or a management discussion (MDA). It is a specific type of corporate update. Given the options, this type of announcement, which is not a formal financial report but a significant corporate update, fits best under the general category of 'Regulatory Filings' (RNS) as a catch-all for important, non-standard disclosures, or potentially an 'Investor Presentation' (IP) if it were a slide deck, but as a press release, RNS is the most appropriate fit among the provided choices for a significant, non-financial-reporting corporate event disclosure. However, upon reviewing the definitions, none perfectly capture a 'Clinical Trial Results Press Release'. RNS is the fallback for miscellaneous regulatory announcements. Since this is a major operational update that impacts the company's future product pipeline and regulatory strategy, RNS is the most suitable classification as a general regulatory disclosure not covered by other specific financial or meeting codes.
2023-10-11 English
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
Regulatory Filings Classification · 95% confidence The document is a press release from ALK-Abelló announcing positive results from a Phase 3 clinical trial for a pediatric allergy tablet. It includes company contact information, a summary of the trial results, and a disclaimer regarding the EU Market Abuse Regulation. While it mentions an attached file, the document itself serves as the primary announcement of the clinical trial results, which falls under the category of a regulatory filing or corporate announcement. Given the specific nature of the content (clinical trial results announcement), it fits best as a Regulatory Filing (RNS) as it is a standard corporate disclosure of material information.
2023-10-11 Danish
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
Regulatory Filings Classification · 95% confidence The document is a press release announcing the results of a Phase 3 clinical trial for a pharmaceutical product. It provides key highlights of the trial's success and future regulatory plans. While it mentions an attachment, the text itself is a substantive announcement of corporate/clinical news rather than just a notification of a report's publication. As it does not fit into specific financial reporting categories like 10-K or IR, and is a standard corporate regulatory announcement, it is classified as a Regulatory Filing (RNS).
2023-10-11 English
Earnings Release 2023
Earnings Release Classification · 100% confidence The document is explicitly titled "Six-month interim report (Q2) 2023" and contains detailed financial highlights for Q2 2023 and the first six months (H1) 2023, including revenue, EBIT, and margin figures, along with forward-looking guidance. This content structure perfectly matches the definition of a comprehensive financial report for a period shorter than a year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Although it mentions a conference call, the primary content is the report itself, not just the announcement of the report. H1 2023
2023-08-24 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Six-month interim report (Q2) 2023' and contains comprehensive financial statements, including income statements, balance sheets, and cash flow data for the first half of the year. It provides detailed management analysis of financial performance, strategic priorities, and future outlook. It is not a mere announcement or certification, but the full interim financial report itself. H1 2023
2023-08-24 English
Six-month interim report (Q2) 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Six-month interim report (Q2) 2023' and contains substantive financial data, including revenue growth, EBIT, EBIT margins, and a detailed breakdown of financial performance for the first six months (H1) of 2023. Although it mentions a conference call and provides a link to an attached file, the document itself provides the actual financial results and analysis, meeting the criteria for an Interim/Quarterly Report (IR) rather than just an announcement. H1 2023
2023-08-24 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.